Cargando…

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

OBJECTIVE: In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 diabetes in adults and children age ≥8 years with stage 2 type 1 diabetes on the basis of data from the pivotal study TN-10. RESEARCH DESIGN AND METHODS: To provide confirmatory evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herold, Kevan C., Gitelman, Stephen E., Gottlieb, Peter A., Knecht, Laura A., Raymond, Ralph, Ramos, Eleanor L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545553/ https://www.ncbi.nlm.nih.gov/pubmed/37607392 http://dx.doi.org/10.2337/dc23-0675

Ejemplares similares

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
por: Herold, Kevan C., et al.
Publicado: (2013)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial
por: Hagopian, William, et al.
Publicado: (2013)

Immune Therapy and β-Cell Death in Type 1 Diabetes
por: Lebastchi, Jasmin, et al.
Publicado: (2013)

Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report
por: Wherrett, Diane K., et al.
Publicado: (2015)

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
por: Jacobsen, Laura M., et al.
Publicado: (2020)

β-Cell Mass and Type 1 Diabetes: Going, Going, Gone?
por: Akirav, Eitan, et al.
Publicado: (2008)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes
por: Boyle, Karen D., et al.
Publicado: (2016)

A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes
por: Herold, Kevan C., et al.
Publicado: (2005)

Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes
por: Simmons, Kimber M., et al.
Publicado: (2019)

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
por: Gitelman, Stephen E., et al.
Publicado: (2023)

New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
por: Nagy, Geza, et al.
Publicado: (2022)

Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies
por: Beam, Craig A., et al.
Publicado: (2014)

Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes
por: Gottlieb, Peter A., et al.
Publicado: (2010)

Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes
por: Anderson, Randy L., et al.
Publicado: (2022)

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
por: Haller, Michael J., et al.
Publicado: (2019)

Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
por: Buckingham, Bruce, et al.
Publicado: (2013)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited
por: Atkinson, Mark A., et al.
Publicado: (2011)

The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
por: Dong, Shen, et al.
Publicado: (2021)

Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes
por: Herold, Kevan C., et al.
Publicado: (2009)

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?
por: Ferrara, Christine Therese, et al.
Publicado: (2017)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes
por: Sims, Emily K., et al.
Publicado: (2023)

Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials
por: Kinney, Mara, et al.
Publicado: (2023)

Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review
por: Felton, Jamie L., et al.
Publicado: (2023)

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
por: Russell, William E., et al.
Publicado: (2023)

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes
por: Perdigoto, Ana Luisa, et al.
Publicado: (2022)

IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
por: Greenbaum, Carla J., et al.
Publicado: (2021)

Goals of Treatment for Type 2 Diabetes: β-Cell preservation for glycemic control
por: Marchetti, Piero, et al.
Publicado: (2009)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes
por: Ku, Elaine, et al.
Publicado: (2016)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial
por: Gitelman, Stephen E., et al.
Publicado: (2016)

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes
por: Linsley, Peter S., et al.
Publicado: (2018)

Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes
por: Rui, Jinxiu, et al.
Publicado: (2021)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_i52mldofgk414g4a7iohvvcdnb